Treating Depression With Antidepressants: Drug-Placebo Efficacy Debates Limit Broader Considerations

American Journal of Clinical Hypnosis

Volumn 55, Issue 3, 2013, Pages 272-290

  Yapko, Michael D ^a  

^a Private Practice   (United States)

Author keywords

depression; drugs; medications; psychotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ADVERTIZING; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL PRACTICE; DANGEROUS GOODS; DEPRESSION; DIZZINESS; ECONOMICS; FRAUD; HEADACHE; HUMAN; HYPNOSIS; INSOMNIA; METHODOLOGY; NAUSEA; PLACEBO EFFECT; RESEARCH; RESTLESSNESS; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; UNITED STATES;

ADVERTISING AS TOPIC; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DIZZINESS; FRAUD; HAZARDOUS SUBSTANCES; HEADACHE; HUMANS; HYPNOSIS; NAUSEA; PHYSICIAN'S PRACTICE PATTERNS; PLACEBO EFFECT; PLACEBOS; PSYCHOMOTOR AGITATION; RESEARCH; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 84872397607     PISSN: 00029157     EISSN: 21600562     Source Type: Journal    
DOI: 10.1080/00029157.2012.707156     Document Type: Article

References (95)

1. Alladin, A. 2006. "Experiential cognitive hypnotherapy: Strategies for relapse prevention in depression". In Hypnosis and treating depression: Advances in clinical practice, Edited by: Yapko, M. 281-313. New York, NY: Routledge.
2. Alladin, A. 2010. Evidence-based hypnotherapy for depression. International Journal of Clinical and Experimental Hypnosis, 58: 165-184.
3. Alladin, A. 2012. Cognitive hypnotherapy for major depressive disorder. American Journal of Clinical Hypnosis, 54: 275-293.
4. Alladin, A. and Alibhai, A. 2007. Cognitive hypnotherapy for depression. International Journal of Clinical and Experimental Hypnosis, 55: 147-166.
5. Angell, M. 2005. The truth about the drug companies: How they deceive us and what to do about it, New York, NY: Random House.
6. Angell, M. (2011, June 23). The epidemic of mental illness: Why? The New York Review of Books. www.nybooks.com/articles/archives/2011/jun/23/epidemic-mental-illness-why/?pagination=false
7. Balon, R. 2007. Psychiatrist attitudes toward self-treatment of their own depression. Psychotherapy and Psychosomatics, 76: 306-310.
8. Banov, M. 2010. Taking antidepressants: Your comprehensive guide to starting, staying on,and safely quitting, North Branch, MN: Sunrise River Press.
9. Barber, C. 2008. Comfortably numb: How psychiatry is medicating a nation, New York, NY: Pantheon.
10. Barclay, L. (2010, January 27). Efficacy of antidepressant medication vs. placebo increases with severity of depression. www.medscape.com/viewarticle/715585
11. Bloom, F. (2010, June 8). Placebo versus antidepressant: Review of the emperor's new drugs. http://dana.org/news/cerebrum/detail.aspx?id=28024
12. Bremner, J. 2008. Before you take that pill: Why the drug industry may be bad for your health, New York, NY: Avery.
13. Bridge, J., Iyengar, S., Salary, C., Barbe, R., Birmaher, B., Pincus, H. and Brent, D. 2007. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. Journal of the American Medical Association, 297: 1683-1696.
14. Brody, A., Saxena, S., Stoessel, P., Gillies, L., Fairbanks, L., Alborzian, S. and Baxter, L. 2001. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: Preliminary findings. Archives of General Psychiatry, 58: 631-640.
15. Buck, M. (2012). The placebo response in pediatric clinical trials. Pediatric Pharmacology, 18, 3. http://www.medscape.com/viewarticle/761908_7
16. Buzby, M. (2008, March 13). Drugs in our drinking water. The Collaborative on Health and the Environment E-Newsletter. http://www.healthandenvironment.org/articles/newsletters/3349
17. Carlat, D. 2010. Unhinged: The trouble with psychiatry-A doctor's revelations about a profession in crisis, New York, NY: Free Press.
18. Cozolino, L. 2006. The neuroscience of human relationships: Attachments and the developing social brain, New York, NY: Norton.
19. Cosgrove, L. 2010, November. Psychiatric taxonomy, psychopharmacology and big pharma. The Tablet, 11: 60-67.
20. Daughton, C. G. 2008. Pharmaceuticals as environmental pollutants: The ramifications for human exposure. International Encyclopedia of Public Health, 5: 66-122.
21. DeAngelis, C. 2008. Impugning the integrity of medical science: The adverse effects of industry influence. Journal of the American Medical Association, 299: 1833-1835.
22. Detweiler-Bedell, J. and Whisman, M. 2005. A lesson in assigning homework: Therapist, client, and task characteristics in cognitive therapy for depression. Professional Psychology: Research and Practice, 36: 219-223.
23. Doidge, N. 2007. The brain that changes itself: Stories of personal triumph from the frontiers of brain science, New York, NY: Penguin.
24. Dodd, S. (2009, December 23). Feds take first steps to regulate drugs in drinking water. Sustainable Cities Collective. http://sustainablecitiescollective.com/index.php?q=scottdodd/7633/feds-take-first-steps-regulate-drugs-drinking-water
25. Donn, J. (2009, April 19). Tons of released drugs taint U.S. water. US News & World Report Science. http://www.usnews.com/science/articles/2009/04/19/tons-of-released-drugs-taint-us-water
26. Donn, J., Mendoza, M. and Pritchard, J. 2008. AP probe finds drugs in drinking water. Associated Press National Investigative Team. Syndicated nationally March 10, 2008.,
27. Fournier, J., DeRubeis, R., Hollon, S., Dimidjian, S., Amsterdam, J., Shelton, R. and Fawcett, J. 2010. Antidepressant drug effects and depression severity: A patient-level meta-analysis. Journal of the American Medical Association, 303: 47-53.
28. Friedman, R. and Leon, A. 2007. Expanding the black box-Depression, antidepressants, and the risk of suicide. New England Journal of Medicine, 356: 2343-2346.
29. Gandhi, T., Weingart, S., Borus, J., Seger, A., Peterson, J., Burdick, E. and Bates, D. 2003. Adverse drug events: Ambulatory care visits for treatment. New England Journal of Medicine, 348: 1556-1564.
30. Gibbons, R., Brown, C., Hur, K., Davis, J. and Mann, J. 2012. Suicidal thoughts and behavior with antidepressant treatment: Reanalysis of the randomized placebo-Controlled studies of Fluoxetine and Venlafaxine. Archives of General Psychiatry, doi:10.1001/archgenpsychiatry.2011.2048
31. Glenmullen, J. 2006. The antidepressant solution: A step-by-step guide to safely overcoming antidepressant withdrawal, dependence, and "addiction.", New York, NY: Free Press.
32. Goodman, S. and Gotlib, I., eds. 2002. Children of depressed parents: Mechanisms of risk and implications for treatment, Washington, DC: American Psychological Association.
33. Halsband, U., Mueller, S., Hinterberger, T. and Strickner, S. 2009. Plasticity changes in the brain in hypnosis and meditation. Contemporary Hypnosis, 26: 194-215.
34. Harris, C. and de Jong, V. 2011. Perspectives on placebo. The Journal of Mind-Body Regulation, 1: 110-111.
35. Healy, D. 2004. Let them eat Prozac: The unhealthy relationship between the pharmaceutical companies and depression New York, NY, New York University
36. Hunter, A., Leuchter, A., Morgan, M. and Cook, I. 2006. Changes in brain function (Quantitative EEG concordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. American Journal of Psychiatry, 163: 1426-1432.
37. Jacobson, N., Martell, C. and Dimidjian, S. 2001. Behavioral activation treatment for depression: Returning to contextual roots. Clinical Psychology: Science and Practice, 8: 255-270.
38. Keers, R. 2012. Will gene-environment interactions explain differential antidepressant response?. Personalized Medicine, 9: 319-322.
39. Kessler, R., Berglund, P., Demler, D., Jin, R., Koretz, D., Merikangas, K. and Wang, P. 2003. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association, 289: 3095-3105.
40. Kihlstrom, J. 2012, February 21. Comments on Kirsch, antidepressants and placebos. Comment posted on. Hypnosis Digest, a listserv for members of the American Society of Clinical Hypnosis.,
41. Kirsch, I. 1990. How expectancies shape experience, Washington, DC: American Psychological Association.
42. Kirsch, I. 1994. Clinical hypnosis as a nondeceptive placebo: Empirically derived techniques. American Journal of Clinical Hypnosis, 37: 95-106.
43. Kirsch, I. 2001. The response set theory of hypnosis: Expectancy and physiology. American Journal of Clinical Hypnosis, 44: 69-73.
44. Kirsch, I. 2006. "Medication and suggestion in the treatment of depression". In Hypnosis and treating depression: Applications in clinical practice Edited by: Yapko, M. 271-280. New York, NY: Routledge
45. Kirsch, I. 2010. The emperor's new drugs: Exploding the antidepressant myth, New York, NY: Basic Books.
46. Kirsch, I., Deacon, B., Huedo-Medina, T., Scoboria, A., Moore, T. and Johnson, R. 2008. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5: e45 doi:10.1371/journal.pmed.0050045
47. Kramer, P. (2011, July 9). In defense of antidepressants. The New York Times. http://www.nytimes.com/2011/07/10/opinion/sunday/10antidepressants.html?pagewanted=all
48. Lacasse, J. and Leo, J. 2005. Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Medicine, 2: e392 doi:10.1371/journal.pmed.0020392
49. Lankton, S. 2006. "Four brief hypnotic interventions in the treatment of depression". In Hypnosis and treating depression: Applications in clinical practice, Edited by: Yapko, M. 25-47. New York, NY: Routledge.
50. Lehrer. 2006. The reinvention of the self. Seed, 2: 62-63.
51. Lynn, S. and Green, J. 2011. The sociocognitive and dissociation theories of hypnosis: Toward a rapprochement. International Journal of Clinical and Experimental Hypnosis, 59: 277-293.
52. Lynn, S. and Kirsch, I. 2006. Essentials of clinical hypnosis: An evidence-based approach, Washington, DC: American Psychological Association.
53. Lynn, S., Malakataris, A., Condon, L., Maxwell, R. and Cleere, C. 2012. Post-traumatic stress disorder: Cognitive hypnotherapy, mindfulness, and acceptance-based treatment approaches. American Journal of Clinical Hypnosis, 54: 311-330.
54. Mark, T., Levit, K. and Buck, J. 2009. Datapoint: Psychotropic drug prescriptions by medical specialty. Psychiatric Services, 60: 1167
55. Martin, S., Martin, E., Rai, S., Richardson, M. and Royall, R. 2001. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: Preliminary findings. Archives of General Psychiatry, 58: 641-649.
56. Mojtabai, R. and Olfson, M. 2011, August. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Affairs, 30: 1434-1442.
57. Moncrieff, J. 2008. The myth of the chemical cure, Basingstoke, UK: Palgrave Macmillan.
58. Muñoz, R., Beardslee, W. and Leykin, Y. 2012. Major depression can be prevented. American Psychologist, 67: 285-295.
59. Nolen-Hoeksema, S. 2000. The role of rumination in depressive disorders and mixed anxiety/depressive symptoms. Journal of Abnormal Psychology, 109: 504-511.
60. Olfson, M. and Marcus, S. 2009. National patterns in antidepressant medication treatment. Archives of General Psychiatry, 66: 848-856.
61. Peterson, M. 2009. Our daily meds: How the pharmaceutical companies transformed themselves into slick marketing machines and hooked the nation on prescription drugs, New York, NY: Picador.
62. Pettit, J. and Joiner, T., eds. 2006. Chronic depression: Interpersonal sources, therapeutic solutions, Washington, DC: American Psychological Association.
63. Psaty, B. and Kronmal, R. 2008. Reporting mortality findings in trials of Rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from Rofecoxib litigation. Journal of the American Medical Association, 299: 1813-1817.
64. Reblin, M. and Uchino, B. 2008. Social and emotional support and its implication for health. Current Opinions in Psychiatry, 21: 201-205.
65. Rosenquist, S. E. this issue. When the bough breaks: Rethinking treatment strategies for perinatal depression. American Journal of Clinical Hypnosis, 55: 291-323.
66. Ross, J., Hill, K., Egilman, D. and Krumholz, H. 2008. Guest authorship and ghostwriting in publications related to Rofecoxib: A case study of industry documents from Rofecoxib litigation. Journal of the American Medical Association, 299: 1800-1812.
67. Rossi, E. 2003. Gene expression, neurogenesis, and healing: Psychosocial genomics and therapeutic hypnosis. American Journal of clinical Hypnosis, 45: 197-216.
68. Roy-Byrne, P. (2012, May 9). Antidepressants work, and depression severity does not matter. Medscape. http://www.medscape.com/viewarticle/761656?src=emailthis
69. Schultz, M., Furlong, E., Kolpin, D., Weiner, S., Schoenfuss, H., Barber, L. and Vajda, A. 2010. Antidepressant pharmaceuticals in two U.S. effluent-impacted streams: Occurrence and fate in water and sediment, and selective uptake in fish neural tissue. Environmental and Science Technology, 44: 1918-1925.
70. Scott, T. 2006. America fooled: The truth about antidepressants, antipsychotics and how we've been deceived, Victoria, TX: Argo Publishing.
71. Sharpe, K. 2012. Coming of age on Zoloft: How antidepressants cheered us up, let us down, and changed who we are, New York, NY: Harper Perennial.
72. Siegel, D. 2007. The mindful brain, New York, NY: Norton.
73. Simpkins, C. and Simpkins, A. 2010. Neuro-hypnosis: Using self-hypnosis to activate the brain for change, New York, NY: W. W. Norton.
74. Smith, B. 2012. Inappropriate prescribing. Monitor on Psychology, 43: 36-40.
75. Thase, M. (2012, May 23). Three depression therapies to watch. Medscape. www.medscape.com/viewarticle/764271
76. Thomas, R. and Peterson, D. 2003. A neurogenic theory of depression gains momentum. Molecular Interventions, 3: 441-444.
77. Turner, E., Matthews, A., Linardatos, E., Tell, R. and Rosenthal, R. 2008. Selective publication of antidepressant trials and its influence on apparent efficacy. The New England Journal of Medicine, 358: 252-260.
78. Weil, A. 2012, March 23. "Spontaneous happiness: The vision of integrative mental health. Presentation at the". In Psychotherapy Networker Symposium Washington, DC
79. Weissman, M. 2005. Families at high and low risk for depression: A 3 generation study. Archives of General Psychiatry, 62: 29-36.
80. Whitaker, R. 2011. Anatomy of an epidemic: Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America, New York, NY: Broadway.
81. World Health Organization. 2002. The world health report 2002: Reducing risks, promoting healthy life, Geneva, Switzerland: Author.
82. Yapko, M. 1992. Hypnosis and the treatment of depressions: Strategies for change, New York, NY: Brunner/Mazel.
83. Yapko, M. 1997. Breaking the patterns of depression, New York, NY: Random House/Doubleday.
84. Yapko, M. 1999. Hand-me-down blues: How to stop depression from spreading in families, New York, NY: St. Martins Griffin.
85. Yapko, M. 2001a. Treating depression with hypnosis: Integrating cognitive-behavioral and strategic approaches, New York, NY: Brunner/Routledge.
86. Yapko, M. 2001b. Hypnosis in treating symptoms and risk factors of major depression. American Journal of Clinical Hypnosis, 44: 97-108.
87. Yapko, M. 2001c. Hypnotic intervention for ambiguity as a depressive risk factor. American Journal of Clinical Hypnosis, 44: 109-117.
88. Yapko, M., ed. 2006. Hypnosis and treating depression: Applications in clinical practice, New York, NY: Routledge.
89. Yapko, M. 2008. "Hypnotic approaches to treating depression". In The Oxford handbook of hypnosis: Theory, research and practice, Edited by: Nash, M. and Barnier, A. 549-567. Oxford, UK: Oxford University Press.
90. Yapko, M. 2009. Depression is contagious: How the most common mood disorder is spreading around the world and how to stop it, New York, NY: Free Press.
91. Yapko, M. 2010a. Hypnosis in the treatment of depression: An overdue approach for encouraging skillful mood management. International Journal of Clinical and Experimental Hypnosis, 58: 137-146.
92. Yapko, M. 2010b. Hypnotically catalyzing experiential learning across treatments for depression: Actions can speak louder than moods. International Journal of Clinical and Experimental Hypnosis, 58: 186-201.
93. Yapko, M. 2011. Mindfulness and hypnosis: The power of suggestion to transform experience, New York, NY: Norton.
94. Yapko, M. 2012. Trancework: An introduction to the practice of clinical hypnosis, 4th, New York, NY: Routledge.
95. Zeig, J. 1990. "Seeding". In Brief therapy: Myths, methods, and metaphors, Edited by: Zeig, J. and Gilligan, S. 221-246. New York, NY: Brunner/Mazel.